• Scheduled checkpoint review of safety clears NOX66 monotherapy
• First group of patients complete Phase 1a arm
• Phase 1b combination treatment now underway
• Full recruitment anticipated by late-July 2017
Sydney, 5 June 2017: Noxopharm announces that clinical study NOX-001 has been given the green light by its Data Safety Monitoring Committee to proceed to complete recruitment of the remaining patients based on the absence of toxicity of the Company’s front-line anti-cancer drug, NOX66.
For further information please download PDF attached:
Download this document
